Time and Motion Study of A Subcutaneous Fixed-Dose Combination Of Pertuzumab And Trastuzumab versus Intravenous Pertuzumab and Trastuzumab for The Neoadjuvant Treatment of Patients With HER2-Positive Early Breast Cancer in Malaysian Public Oncology Centres
HER2-Positive Early Breast Cancer
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
NOOR ZAFIFAH BINTI ZAKARIA
CONTACT
SC: Irdina Fakhira Mohd Fadzir
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
SANGEETA A/P VAHNALINGAM
CONTACT
SC: Nur Amiera Wahida Azman
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node positive, Estrogen Receptor positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
EZNAL IZWADI BIN MOHD MAHIDIN
CONTACT
Nurul Aiman Farhana Nor Aziz Hashim
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
NOR HAYATI BINTI HASHIM
CONTACT
Oh Bi Han
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
SUHANA BINTI YUSAK
CONTACT
Sarah Khairul Annuar
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
CHOONG SWEE HSIA
CONTACT
Nur Farissha Ilyiana Mohamad Pisol
Raja Permaisuri Bainun Hospital, Ipoh
PRINCIPAL INVESTIGATOR
Angel Kwan Khor Nee
CONTACT
Nurnabiha Syifaa Binti Nasir
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
Dr Mastura Md Yusof
CONTACT
Aini Rasidda Norazmi
CRC: 03-22960888 Ext.1320, 1321, 1322
A Phase III,Open Label, Randomised study to Assess the Efficacy and Safety of Extend Therapy with Camizestrant (AZD9833, a Next Generation , Oral Selective Estrogen Receptor Degrade) Versus standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in patient with ER+/HER2- Early Breast Cancer and an intermediate or High Risk of Recurrence Who have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine–Based Therapy without Disease Recurrence. (CAMBRIA-1)
Prince Court Medical Centre
PRINCIPAL INVESTIGATOR
Dr Muhammad Azrif Ahmad Annuar
CONTACT
SC: Punitha Somasundram
Email: punitha.somasundram@princecourt.com
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
NAJIHAH BINTI ABU BAKAR
CONTACT
SC: Nur Fadhilah Megat Ismail
Hospital Wanita dan Kanak-Kanak Sabah
PRINCIPAL INVESTIGATOR
FLORA CHONG LI TZE
CONTACT
SC: Nancy Nuau
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
SOO HOO HWOEI FEN
CONTACT
SC: Nur Rasyidah Muhammad
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Ngu Ming Ruey
CONTACT
SC: Tan Boon Sin
Sultan Ismail Hospital
PRINCIPAL INVESTIGATOR
LIM CHUN SEN
CONTACT
SC: Sri Ratha Balakrishnan
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery (TroFuse-012)
Prince Court Medical Centre
PRINCIPAL INVESTIGATOR
Dr Muhammad Azrif Ahmad Annuar
CONTACT
SC: Tan Woan Lee
Email: woanlee.tan@princecourt.com
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03-22960888 Ext.1320, 1321, 1322